Patients who had adjuvant Verzenio with endocrine therapy had a small but significant improvement in survival versus endocrine therapy alone.

Kite has paid $120 million upfront to Pregene to gain certain license rights and to collaborate on developing in vivo cell therapies with the Shenzhen, China-based firm. Pregene is entitled to receive ...

The agency launched the Commissioner's National Priority Voucher pilot program to quickly approve products that could address national interests.

Trial initiation triggered a $250 million payment to SystImmune from Bristol Myers Squibb, under a 2023 collaboration and license agreement.